Skip to main content

CH-FIT trial

Interested in our Congenital Heart Fitness Intervention Trial?

Find out more

Our ongoing studies have successfully developed a novel in vivo model of thrombolysis (iCAT) that for the first time allows us the ability to examine the efficacy of novel drugs including novel thrombin inhibitors to facilitate clot lysis (recanalization), restore perfusion in the brain, as well as determine whether cerebral damage and cognitive impairment associated with stroke are reduced. We are using this model to assess the efficacy of currently approved and novel anticlotting agents to facilitate stroke treatment.

Interested in our Congenital Heart…

Find out more